Effect of Epidermal Growth Factor Receptor Inhibitors on Magnesium Homeostasis in Patients With Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898027|
Recruitment Status : Terminated (slow accrual)
First Posted : May 12, 2009
Last Update Posted : January 29, 2013
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving epidermal growth factor receptor inhibitors may help doctors understand the effect of epidermal growth factor receptor inhibitors on magnesium levels in the body.
PURPOSE: This laboratory study is looking at the effect of epidermal growth factor receptor inhibitors on magnesium homeostasis in patients with cancer.
|Condition or disease||Intervention/treatment|
|Solid Tumor||Other: laboratory biomarker analysis|
- Determine the effects of EGFR inhibitors on magnesium homeostasis in patients with cancer.
OUTLINE: This is a pilot study.
Patients undergo blood and urine sample collection at baseline and at 2, 4, and 8 weeks during treatment.
After finishing treatment, patients are followed periodically for up to 10 weeks.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on Magnesium Homeostasis|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||March 2008|
|Actual Study Completion Date :||February 2009|
- Other: laboratory biomarker analysis
laboratory biomarker analysis
- Effects of EGFR inhibitors on magnesium homeostasis [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898027
|Principal Investigator:||Laura Goff, MD||Vanderbilt-Ingram Cancer Center|